MedTrace Logo

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

NCT00281021 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

Erlotinib plus Digoxin

Each subject will receive erlotinib and digoxin daily until progression.

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Goetz H Kloecker, MD, MSPH · James Graham Brown Cancer Center/ University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00281021 on ClinicalTrials.gov